Reversion of multidrug resistance using nanoparticles in vitro: Influence of the nature of the polymer

被引:57
作者
Nemati, F
Dubernet, C
Fessi, H
deVerdiere, AC
Poupon, MF
Puisieux, F
Couvreur, P
机构
[1] UNIV PARIS SUD,URA CNRS 1218,CTR ETUD PHARMACEUT,F-92296 CHATENAY MALABRY,FRANCE
[2] UNIV LYON,LAB PHARMACOTECH,LYON,FRANCE
[3] URA CNRS 620,F-75231 PARIS 05,FRANCE
关键词
nanoparticles; doxorubicin; polyalkylcyanoacrylate alginate; polylactide; P388; multidrug resistance; reversion;
D O I
10.1016/0378-5173(96)04559-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Previous studies have already shown that polyalkylcyanoacrylate nanoparticles were able to overcome multidrug resistance in vitro. The study described in this paper investigated other types of nanoparticles, made of poly (lactic acid) PLA, poly (lactic-co-glycolic acid) PLGA and alginate, in order to determine if overcoming of resistance could be achieved with any nanoparticles independently of the nature of the polymer. In a first step, PLA and PLGA nanoparticles loaded with doxorubicin have been formulated, and the cytotoxicity of each preparation has been evaluated against P388 sensitive and resistant cells. Only polyalkylcyanoacrylate nanoparticles were effective: doxorubicin release experiments allowed to incriminate too rapid doxorubicin release in the case of PLA, PLGA and alginate nanoparticles to explain their lack of efficacy to overcome MDR.
引用
收藏
页码:237 / 246
页数:10
相关论文
共 20 条
[1]  
BENNIS S, 1993, EUR J CANCER, V30, P106
[2]   MECHANISM OF MULTIDRUG RESISTANCE [J].
BRADLEY, G ;
JURANKA, PF ;
LING, V .
BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 948 (01) :87-128
[3]   ENTRAPMENT OF BETA-LACTAMS ANTIBIOTICS IN POLYETHYLCYANOACRYLATE NANOPARTICLES - STUDIES ON THE POSSIBLE IN-VIVO APPLICATION OF THIS COLLOIDAL DELIVERY SYSTEM [J].
CAVALLARO, G ;
FRESTA, M ;
GIAMMONA, G ;
PUGLISI, G ;
VILLARI, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 111 (01) :31-41
[4]   POLYCYANOACRYLATE NANOCAPSULES AS POTENTIAL LYSOSOMOTROPIC CARRIERS - PREPARATION, MORPHOLOGICAL AND SORPTIVE PROPERTIES [J].
COUVREUR, P ;
KANTE, B ;
ROLAND, M ;
GUIOT, P ;
BAUDUIN, P ;
SPEISER, P .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1979, 31 (05) :331-332
[5]   DOXORUBICIN-LOADED NANOSPHERES BYPASS TUMOR-CELL MULTIDRUG RESISTANCE [J].
CUVIER, C ;
ROBLOTTREUPEL, L ;
MILLOT, JM ;
LIZARD, G ;
CHEVILLARD, S ;
MANFAIT, M ;
COUVREUR, P ;
POUPON, MF .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (03) :509-517
[6]  
DEVERDIERE AC, 1994, CANCER CHEMOTH PHARM, V33, P504
[7]  
FESSI H, 1988, Patent No. 274961
[8]   PROBING THE INTERACTIONS OF THE ANTICANCER DRUG DOXORUBICIN WITH POLYMERIC NANOPARTICLES USING FLUORESCENCE SPECTROSCOPY [J].
HENRYTOULME, N ;
DECOUT, A ;
LALANNE, J ;
NEMATI, F ;
DUBERNET, C ;
DUFOURCQ, J .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 1994, 162 (01) :236-243
[9]   ABSORPTION AND CIRCULAR DICHROIC SPECTRAL STUDIES ON THE SELF-ASSOCIATION OF DAUNORUBICIN [J].
MARTIN, SR .
BIOPOLYMERS, 1980, 19 (03) :713-721
[10]   SOME PARAMETERS INFLUENCING CYTOTOXICITY OF FREE DOXORUBICIN AND DOXORUBICIN-LOADED NANOPARTICLES IN SENSITIVE AND MULTIDRUG-RESISTANT LEUKEMIC MURINE CELLS - INCUBATION-TIME, NUMBER OF NANOPARTICLES PER CELL [J].
NEMATI, F ;
DUBERNET, C ;
DEVERDIERE, AC ;
POUPON, MF ;
TREUPELACAR, L ;
PUISIEUX, F ;
COUVREUR, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 102 (1-3) :55-62